These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 19075700)
1. Anti-amyloidogenic/protein-misfolding therapies in amyloidosis and other protein-misfolding disorders. Yamada M Curr Pharm Des; 2008; 14(30):3203-4. PubMed ID: 19075700 [No Abstract] [Full Text] [Related]
2. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Sekijima Y; Kelly JW; Ikeda S Curr Pharm Des; 2008; 14(30):3219-30. PubMed ID: 19075702 [TBL] [Abstract][Full Text] [Related]
3. [Characterization of amyloidosis]. Yazaki M; Ikeda S Brain Nerve; 2014 Jul; 66(7):723-30. PubMed ID: 24998817 [TBL] [Abstract][Full Text] [Related]
4. Misfolding the way to disease. Taubes G Science; 1996 Mar; 271(5255):1493-5. PubMed ID: 8599100 [No Abstract] [Full Text] [Related]
5. The Role of Proteolysis in Amyloidosis. Acquasaliente L; De Filippis V Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614141 [TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of amyloidosis. Kisilevsky R; Young ID Baillieres Clin Rheumatol; 1994 Aug; 8(3):613-26. PubMed ID: 7954865 [No Abstract] [Full Text] [Related]
7. Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic transthyretin misfolding in transthyretin-related amyloidosis. Jono H; Anno T; Motoyama K; Misumi Y; Tasaki M; Oshima T; Mori Y; Mizuguchi M; Ueda M; Shono M; Obayashi K; Arima H; Ando Y Biochem J; 2011 Jul; 437(1):35-42. PubMed ID: 21668413 [TBL] [Abstract][Full Text] [Related]
9. [Transthyretin amyloidoses]. Magy-Bertrand N Rev Med Interne; 2007 May; 28(5):306-13. PubMed ID: 17316923 [TBL] [Abstract][Full Text] [Related]
10. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Hammarström P; Wiseman RL; Powers ET; Kelly JW Science; 2003 Jan; 299(5607):713-6. PubMed ID: 12560553 [TBL] [Abstract][Full Text] [Related]
11. [Amyloidosis: a model of misfolded protein disorder]. Grateau G; Verine J; Delpech M; Ries M Med Sci (Paris); 2005; 21(6-7):627-33. PubMed ID: 15985206 [TBL] [Abstract][Full Text] [Related]
12. Common Fibril Structures Imply Systemically Conserved Protein Misfolding Pathways In Vivo. Annamalai K; Liberta F; Vielberg MT; Close W; Lilie H; Gührs KH; Schierhorn A; Koehler R; Schmidt A; Haupt C; Hegenbart U; Schönland S; Schmidt M; Groll M; Fändrich M Angew Chem Int Ed Engl; 2017 Jun; 56(26):7510-7514. PubMed ID: 28544119 [TBL] [Abstract][Full Text] [Related]
15. Amyloid disease prevention by transthyretin native state complexation with carborane derivatives lacking cyclooxygenase inhibition. Julius RL; Hawthorne MF Drug News Perspect; 2008 Jun; 21(5):258-66. PubMed ID: 18596990 [TBL] [Abstract][Full Text] [Related]
16. Treatment and prevention of the amyloidoses: can the lessons learned be applied to sporadic inclusion-body myositis? Buxbaum JN Neurology; 2006 Jan; 66(2 Suppl 1):S110-3. PubMed ID: 16432137 [TBL] [Abstract][Full Text] [Related]
17. Clearance of extracellular misfolded proteins in systemic amyloidosis: experience with transthyretin. Almeida MR; Saraiva MJ FEBS Lett; 2012 Aug; 586(18):2891-6. PubMed ID: 22819819 [TBL] [Abstract][Full Text] [Related]